This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peterson, J. W.
Right arrow Articles by Chopra, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peterson, J. W.
Right arrow Articles by Chopra, A. K.

 Previous Article  |  Next Article 

Infection and Immunity, February 1999, p. 794-799, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Cholera Toxin B Subunit Activates Arachidonic Acid Metabolism

Johnny W. Peterson,1,* Richard A. Finkelstein,2 Juan Cantu,1 Deborah L. Gessell,1 and Ashok K. Chopra1

Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas 77555-1070,1 and Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri 652122

Received 31 August 1998/Returned for modification 20 October 1998/Accepted 9 November 1998

Cholera toxin (CT) increases intestinal secretion of water and electrolytes and modulates the mucosal immune response by stimulating cellular synthesis of arachidonic acid (AA) metabolites (e.g., prostaglandin E2), as well as the intracellular second messenger cyclic AMP (cAMP). While much is known about the mechanism of CT stimulation of adenylate cyclase, the toxin's activation of phospholipase A2, which results in increased hydrolysis of AA from membrane phospholipids, is not well understood. To determine whether CT activation of AA metabolism requires CT's known enzymatic activity (i.e., ADP-ribosylation of GSalpha ), we used native CT and a mutant CT protein (CT-2*) lacking ADP-ribose transferase activity in combination with S49 wild-type (WT) and S49 cyc- murine Theta (Th)1.2-positive lymphoma cells deficient in GSalpha . The experimental results showed that native CT stimulated the release of [3H[AA from S49 cyc- cells at a level similar to that for S49 WT cells, indicating that GSalpha is not essential for this process. Further, levels of cAMP in the CT-treated cyc- cells remained the same as those in the untreated control cells. The ADP-ribosyltransferase-deficient CT-2* protein, which was incapable of increasing synthesis of cAMP, displayed about the same capacity as CT to evoke the release of [3H]AA metabolites from both S49 WT and cyc- cells. We concluded that stimulation of arachidonate metabolism in S49 murine lymphoma cells by native CT does not require enzymatically functional CT, capable of catalyzing the ADP-ribosylation reaction. These results demonstrated for the first time that stimulation of adenylate cyclase by CT and stimulation of AA metabolism by CT are not necessarily coregulated. In addition, the B subunits purified from native CT and CT-2* both simulated the release of [3H]AA from S49 cyc- cells and murine monocyte/macrophage cells (RAW 264.7), suggesting a receptor-mediated cell activation process of potential importance in enhancing immune responses to vaccine components.


* Corresponding author. Mailing address: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-1070. Phone: (409) 772-4910. Fax: (409) 747-6869. E-mail: johnny.peterson{at}utmb.edu.


Infection and Immunity, February 1999, p. 794-799, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Boyaka, P. N., Ohmura, M., Fujihashi, K., Koga, T., Yamamoto, M., Kweon, M.-N., Takeda, Y., Jackson, R. J., Kiyono, H., Yuki, Y., McGhee, J. R. (2003). Chimeras of Labile Toxin One and Cholera Toxin Retain Mucosal Adjuvanticity and Direct Th Cell Subsets Via Their B Subunit. J. Immunol. 170: 454-462 [Abstract] [Full Text]  
  • Torgersen, M. L., Skretting, G., van Deurs, B., Sandvig, K. (2002). Internalization of cholera toxin by different endocytic mechanisms. J. Cell Sci. 114: 3737-3747 [Abstract] [Full Text]  
  • Johnson-Henry, K., Wallace, J. L., Basappa, N. S., Soni, R., Wu, G. K. P., Sherman, P. M. (2001). Inhibition of Attaching and Effacing Lesion Formation following Enteropathogenic Escherichia coli and Shiga Toxin-Producing E. coli Infection. Infect. Immun. 69: 7152-7158 [Abstract] [Full Text]  
  • Beubler, E., Schuligoi, R., Chopra, A. K., Ribardo, D. A., Peskar, B. A. (2001). Cholera Toxin Induces Prostaglandin Synthesis via Post-Transcriptional Activation of Cyclooxygenase-2 in the Rat Jejunum. J. Pharmacol. Exp. Ther. 297: 940-945 [Abstract] [Full Text]  
  • Simmons, C. P., Mastroeni, P., Fowler, R., Ghaem-maghami, M., Lycke, N., Pizza, M., Rappuoli, R., Dougan, G. (1999). MHC Class I-Restricted Cytotoxic Lymphocyte Responses Induced by Enterotoxin-Based Mucosal Adjuvants. J. Immunol. 163: 6502-6510 [Abstract] [Full Text]